Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Leukemia

Volumn 29, Issue 2, 2015, Pages 312-320

  Walter, R B ^a,b   Othus, M ^a   Burnett, A K ^c   Lowenberg B ^d   Kantarjian, H M ^e   Ossenkoppele, G J ^f   Hills, R K ^c   Ravandi, F ^e   Pabst, T ^g   Evans, A ^c   Pierce, S R ^e   Vekemans, M C ^h   Appelbaum, F R ^b   Estey, E H ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF BERN   (Switzerland)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CANCER CENTER; CANCER RESISTANCE; CYTOGENETICS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG RESISTANCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; REGRESSION ANALYSIS; REMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; REGRESSION ANALYSIS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922429991     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.242     Document Type: Article

References (35)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006; 368 : 1894-1907.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381: 484-495.
4. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360-3368.
5. Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012; 119: 551-558.
6. Harrell FE Jr. Regression Modeling Strategies: With Applications To Linear Models, Logistic Regression, And Survival Analysis. Springer: New York, NY, USA, 2001.
7. Pepe MS. The Statistical Evaluation Of Medical Tests For Classification And Prediction. Oxford University Press: New York, NY, USA, 2004.
8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue 4th edn. IARC: Lyon, France, 2008.
9. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417-4423.
10. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Muller MP, Tomlinson G, Marrie TJ, Tang P, McGeer A, Low DE et al. Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia? Clin Infect Dis 2005; 40: 1079-1086.
13. Ishihara R, Yamada T, Iishi H, Kato M, Yamamoto S, Yamamoto S et al. Quantitative analysis of the color change after iodine staining for diagnosing esophageal highgrade intraepithelial neoplasia and invasive cancer. Gastrointest Endosc 2009; 69: 213-218.
14. Roelen CA, van Rhenen W, Groothoff JW, van der Klink JJ, Bultmann U, Heymans MW. The development and validation of two prediction models to identify employees at risk of high sickness absence. Eur J Public Health 2013; 23: 128-133.
15. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
16. Harrell FE Jr, Margolis PA, Gove S, Mason KE, Mulholland EK, Lehmann D et al. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. WHO/ARI Young Infant Multicentre Study Group. Stat Med 1998; 17: 909-944.
17. Othus M, Appelbaum FR, Petersdorf S, Erba HP, Estey EH. Evaluation of which patients get a second course of 3+7 on cooperative group trials for newly diagnosed acute myeloid leukemia: a report from SWOG [abstract]. Blood 2013; 122: 3925.
18. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
19. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 2008; 93: 633-634.
20. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008.
21. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117 : 2469-2475.
22. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
23. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643.
24. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920-6929.
25. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119 : 2114-2121.
26. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
27. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098.
28. Haferlach T, Kern W, Schoch C, Schnittger S, Sauerland MC, Heinecke A et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004; 89: 408-418.
29. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172-4174.
30. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120: 1581-1588.
31. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009; 23: 350-357.
32. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123-4131.
33. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. J Clin Oncol 2013; 31: 3889-3897.
34. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
35. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.